Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy

L. Labedzki, H. R. Ochs, D. R. Abernethy, D. J. Greenblatt

Research output: Contribution to journalArticle

Abstract

Serum lidocaine concentrations were measured in a series of ten patients during and after topical lidocaine spray anesthesia used for diagnostic fiberoptic bronchoscopy. Mean total dose of lidocaine ranged from 480–720 mg. Peak serum lidocaine concentrations averaged 3.6 ώg/ml (range: 1.9 to 7.4 µg/ml), and were attained shortly after the start of the procedure. Repeated topical administration of lidocaine spray therefore may lead to large cumulative doses and serum concentrations which are in the therapeutic or potentially toxic range.

Original languageEnglish (US)
Pages (from-to)379-380
Number of pages2
JournalKlinische Wochenschrift
Volume61
Issue number7
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Poisons
Bronchoscopy
Lidocaine
Anesthesia
Serum
Topical Administration

Keywords

  • Bronchoscopy
  • Serum lidocaine concentrations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy. / Labedzki, L.; Ochs, H. R.; Abernethy, D. R.; Greenblatt, D. J.

In: Klinische Wochenschrift, Vol. 61, No. 7, 1983, p. 379-380.

Research output: Contribution to journalArticle

Labedzki, L. ; Ochs, H. R. ; Abernethy, D. R. ; Greenblatt, D. J. / Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy. In: Klinische Wochenschrift. 1983 ; Vol. 61, No. 7. pp. 379-380.
@article{4dc2a4b199b14278874a6b71985051c5,
title = "Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy",
abstract = "Serum lidocaine concentrations were measured in a series of ten patients during and after topical lidocaine spray anesthesia used for diagnostic fiberoptic bronchoscopy. Mean total dose of lidocaine ranged from 480–720 mg. Peak serum lidocaine concentrations averaged 3.6 ώg/ml (range: 1.9 to 7.4 µg/ml), and were attained shortly after the start of the procedure. Repeated topical administration of lidocaine spray therefore may lead to large cumulative doses and serum concentrations which are in the therapeutic or potentially toxic range.",
keywords = "Bronchoscopy, Serum lidocaine concentrations",
author = "L. Labedzki and Ochs, {H. R.} and Abernethy, {D. R.} and Greenblatt, {D. J.}",
year = "1983",
doi = "10.1007/BF01485032",
language = "English (US)",
volume = "61",
pages = "379--380",
journal = "Journal of Molecular Medicine",
issn = "0946-2716",
publisher = "Springer Verlag",
number = "7",

}

TY - JOUR

T1 - Potentially toxic serum lidocaine concentrations following spray anesthesia for bronchoscopy

AU - Labedzki, L.

AU - Ochs, H. R.

AU - Abernethy, D. R.

AU - Greenblatt, D. J.

PY - 1983

Y1 - 1983

N2 - Serum lidocaine concentrations were measured in a series of ten patients during and after topical lidocaine spray anesthesia used for diagnostic fiberoptic bronchoscopy. Mean total dose of lidocaine ranged from 480–720 mg. Peak serum lidocaine concentrations averaged 3.6 ώg/ml (range: 1.9 to 7.4 µg/ml), and were attained shortly after the start of the procedure. Repeated topical administration of lidocaine spray therefore may lead to large cumulative doses and serum concentrations which are in the therapeutic or potentially toxic range.

AB - Serum lidocaine concentrations were measured in a series of ten patients during and after topical lidocaine spray anesthesia used for diagnostic fiberoptic bronchoscopy. Mean total dose of lidocaine ranged from 480–720 mg. Peak serum lidocaine concentrations averaged 3.6 ώg/ml (range: 1.9 to 7.4 µg/ml), and were attained shortly after the start of the procedure. Repeated topical administration of lidocaine spray therefore may lead to large cumulative doses and serum concentrations which are in the therapeutic or potentially toxic range.

KW - Bronchoscopy

KW - Serum lidocaine concentrations

UR - http://www.scopus.com/inward/record.url?scp=0020636894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020636894&partnerID=8YFLogxK

U2 - 10.1007/BF01485032

DO - 10.1007/BF01485032

M3 - Article

C2 - 6865269

AN - SCOPUS:0020636894

VL - 61

SP - 379

EP - 380

JO - Journal of Molecular Medicine

JF - Journal of Molecular Medicine

SN - 0946-2716

IS - 7

ER -